198 related articles for article (PubMed ID: 24934696)
1. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?
Dschietzig TB
Am J Cardiovasc Drugs; 2014 Oct; 14(5):343-55. PubMed ID: 24934696
[TBL] [Abstract][Full Text] [Related]
2. Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials.
Dschietzig TB
Mol Cell Endocrinol; 2019 May; 487():54-58. PubMed ID: 30659842
[TBL] [Abstract][Full Text] [Related]
3. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
[TBL] [Abstract][Full Text] [Related]
4. Serelaxin a novel treatment for acute heart failure.
Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
[TBL] [Abstract][Full Text] [Related]
5. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
[TBL] [Abstract][Full Text] [Related]
6. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
[TBL] [Abstract][Full Text] [Related]
7. Serelaxin : a potential new drug for the treatment of acute heart failure.
Neverova N; Teerlink JR
Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798
[TBL] [Abstract][Full Text] [Related]
8. Relaxin: a novel agent for the treatment of acute heart failure.
Wilson SS; Ayaz SI; Levy PD
Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
[TBL] [Abstract][Full Text] [Related]
9. Design of the RELAXin in acute heart failure study.
Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
[TBL] [Abstract][Full Text] [Related]
10. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
Kumar VA; Wilson SS; Ayaz SI; Levy PD
Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
[TBL] [Abstract][Full Text] [Related]
11. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
Díez J
Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
[TBL] [Abstract][Full Text] [Related]
12. Serelaxin and acute heart failure.
Tietjens J; Teerlink JR
Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
[TBL] [Abstract][Full Text] [Related]
13. Representativeness of RELAX-AHF clinical trial population in acute heart failure.
Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF
Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552
[TBL] [Abstract][Full Text] [Related]
14. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
[TBL] [Abstract][Full Text] [Related]
15. [The RELAX-AHF study].
Mortara A
G Ital Cardiol (Rome); 2015 Apr; 16(4):193-7. PubMed ID: 25959752
[No Abstract] [Full Text] [Related]
16. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
Díez J; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of serelaxin in acute heart failure.
Du XJ; Hewitson TD; Nguyen MN; Samuel CS
Circ J; 2014; 78(3):542-52. PubMed ID: 24451687
[TBL] [Abstract][Full Text] [Related]
18. Relaxin, a pleiotropic vasodilator for the treatment of heart failure.
Teichman SL; Unemori E; Dschietzig T; Conrad K; Voors AA; Teerlink JR; Felker GM; Metra M; Cotter G
Heart Fail Rev; 2009 Dec; 14(4):321-9. PubMed ID: 19101795
[TBL] [Abstract][Full Text] [Related]
19. Relaxin: a new approach for the treatment of acute congestive heart failure.
Grossman J; Frishman WH
Cardiol Rev; 2010; 18(6):305-12. PubMed ID: 20926940
[TBL] [Abstract][Full Text] [Related]
20. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
Ng TM; Goland S; Elkayam U
Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
